Copyright ©The Author(s) 2015.
World J Stem Cells. Jun 26, 2015; 7(5): 815-822
Published online Jun 26, 2015. doi: 10.4252/wjsc.v7.i5.815
Table 1 Examples of clinical studies of stem cell therapy used in the treatment of stress urinary incontinence showing a comparison of stem cell source, the duration of in vitro expansion and the follow up of patients post treatment
Origin of stem cells and duration of in vitro expansionNumber of women and route of injectionFollow up (yr)Success rate (improvement and cure)Ref.
Autologous muscle derived stem cells (SC), expanded 8-10 d16 female patients, transurethral approach2Up to 75%[76]
Muscle derived SC222 male patients, transurethral injection1Up to 54%[77]
Minced autologous muscle cells, no in vitro expansion35 female patients1Up to 63%. Improvement (clinical, diary, and ICIQ-SF scores)[78]
Muscle derived SC, expansion duration NA8 female patients, transurethral injection1Significant improvement in 5 women (pad-weight, bladder diary and QOL assessment)[79]
Muscle derived SC, expanded in vitro for 7 wk20 female patients2Significant improvement (clinical, QOL and cystometry). Therapy based on this method is now licensed in Europe[80]
ASCs combined with bovine collagen5 female patients12 out of 5 patients were satisfied with treatment with negative cough test[81]
Autologous ASCs with and without fat11 male patients with post-prostatectomy incontinence160% improvement in urine leakage, frequency and amount of incontinence in 8 patients with one patient achieved total continence[82]